Answers are grounded in this paper and cite their sources.
INTRODUCTION Postmenopausal estrogen decline may contribute to Alzheimer's disease (AD), but evidence linking circulating estrogens to cerebrospinal fluid (CSF) AD biomarkers remains limited. METHODS We analyzed 854 female participants from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study with baseline serum estradiol and estrone measured by liquid chromatography–tandem mass spectrometry and repeated CSF amyloid‐beta 42 (Aβ 42 ), phosphorylated tau 181 (pTau 181 ), and total tau (tTau). Models used regression for cross‐sectional analyses and mixed‐effects models restricted to the 187 participants with follow‐up, adjusted for age, body mass index, waist circumference, and hormone replacement therapy (HRT) use. We also tested apolipoprotein E ε4 ( APOEε4 ) and amyloid moderation and conducted sensitivity analyses excluding current HRT users. RESULTS Neither hormone was associated with Aβ 42 . Higher estradiol was associated with lower baseline tau, especially among APOEε4 carriers, but not with tau change. In exploratory longitudinal analyses, estrone showed a modest association with slower pTau 181 increase. DISCUSSION Findings suggest more consistent cross‐sectional associations of estradiol with tau than with Aβ 42 ; longitudinal findings were limited by attrition and should be interpreted as exploratory.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: